Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77476 | 0.75 | ALDH1A1 (0.36) | ALDH1A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL11231650 | 0.75 | ADORA3 (0.34) | ALDH1A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1400082 | 0.70 | — | — | |
| SCHEMBL20907802 | 0.70 | — | — | |
| SCHEMBL12245280 | 0.68 | CCNE2 (0.33) | — | |
| SCHEMBL175478 | 0.67 | ALDH1A1 (0.33) | ALDH1A1ADORA2AHPGDNPC1RAB9A | |
| SCHEMBL12298052 | 0.65 | — | — | |
| SCHEMBL20285553 | 0.65 | PTGS1 (0.37) | — | |
| SCHEMBL26699006 | 0.65 | PDE4A (0.34) | — | |
| SCHEMBL12798682 | 0.65 | TLR7 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| US-10653681-B2 | Analgesic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190111031-A1 | ANALGESIC COMPOUNDS | KTHERA, LLC | 2019-04-18 | — | — | US | disclosed |
| EP-3455220-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3456355-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2019-03-20 | — | — | EP | disclosed |
| CN-109310679-A | Combination comprising histone deacetylase inhibitor | 卡鲁斯治疗有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-9862685-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-01-09 | — | — | US | disclosed |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | ARIMORI SADAYUKI | 2011-07-14 | — | — | US | disclosed |
| US-7935716-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| WO-2010055164-A2 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-05-20 | — | — | WO | disclosed |
| US-20090076063-A1 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1887002-A1 | CARBOXAMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-4337081-A | 5-Amido-3-trihalomethyl-1,2,4-thiadiazoles and their use as herbicides | OLIN CORPORATION (US) | 1982-06-29 | — | — | US | disclosed |
| US-4254265-A | Selected 5-trichloromethylthioamino derivatives of 3-trihalomethyl-1,2,4-thiadiazole and their use as fungicides | OLIN CORPORATION (US) | 1981-03-03 | — | — | US | disclosed |
| US-4228289-A | POSTEMERGENCE HERBICIDES | OLIN CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
| US-4224449-A | HERBICIDES | OLIN CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4207089-A | Thiolcarbamate derivatives of 3-trihalomethyl-1,2,4-thiadiazoles and their use as herbicides | OLIN CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076063-A1 | Carboxamide compound and use of the same | CBR3, SIRT2, SIRT1 | ALDH1A1 3016/4885ADORA3 2582/4885ADORA2A 3102/4885 |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | CBR3, SIRT2, SIRT1 | ALDH1A1 3016/4885ADORA3 2582/4885ADORA2A 3102/4885 |
| US-20190111031-A1 | ANALGESIC COMPOUNDS | OPRK1, OPRL1, OPRM1 | ALDH1A1 113/4885ADORA3 371/4885ADORA2A 243/4885 |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC11 | ALDH1A1 630/4885ADORA3 4783/4885ADORA2A 4816/4885 |
| US-10870624-B2 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC2 | ALDH1A1 584/4885ADORA3 4739/4885ADORA2A 4754/4885 |
| US-10653681-B2 | Analgesic compounds | OPRK1, OPRL1, OPRM1 | ALDH1A1 113/4885ADORA3 371/4885ADORA2A 243/4885 |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | MCL1, HDAC1, MYC | ALDH1A1 1515/4885ADORA3 4724/4885ADORA2A 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.